1-(2-Naphthalen-1-ylethyl)-7-pyrimidin-4-ylimidazo[1,2-a]pyrimidin-5-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(2-Naphthalen-1-ylethyl)-7-pyrimidin-4-ylimidazo[1,2-a]pyrimidin-5-one
• 化学式: C₂₂H₁₇N₅O
• 分子量: 367.4
• InChiKey: GTWWPMGBWYPGNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  61.7
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
  申请人：SANOFI-SYNTHELABO

  公开号：EP1340759A1

  公开（公告）日：2003-09-03

  The invention relates to a imidazo[1,2-a]pyrimidone derivative represented by formula (I) or a salt thereof: Wherein: X represents a bond, an ethenylene group, an ethynylene group, a methylene group optionally substituted; a carbonyl group, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group or a nitrogen atom being optionally substituted; R1 represents a 2, 4 or 5-pyrimidinyl optionally substituted; R2 represents a C1-6 alkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a benzyl group, a phenyl ring, a naphthyl ring, 5,6,7,8-tetrahydronaphthyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring, the benzyl group and the rings being optionally substituted; and n represents 0 to 3. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明涉及一种由式(I)表示的咪唑并[1,2-a]嘧啶酮衍生物或其盐： 其中，X代表一个键，一个乙烯基，一个乙炔基，一个甲基基团可选择性地被取代的羰基，一个氧原子，一个硫原子，一个磺酰基，一个亚磺酸基或一个氮原子，R1代表一个选择性取代的2、4或5-嘧啶基，R2代表一个C1-6烷基，一个C1-2全氟烷基，一个C1-3卤代烷基，一个苄基，一个苯环，一个萘环，5,6,7,8-四氢萘环，一个吡啶环，一个吲哚环，一个吡咯环，一个噻吩环，一个呋喃环或一个咪唑环，其中苄基和环可选择性地被取代，n代表0到3。 本发明还涉及一种药物，其包含所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活动引起的神经退行性疾病，例如阿尔茨海默病。
• 1-[alkyl 1-[heteroaryl )alkyl] and 1-[ aryl) alkyl]-7-( pyrimidin-4-yl) imadazo [1,2-a] pyrimidin-5(1h)-one derivatives
  申请人：Lochead Alistair

  公开号：US20050119280A1

  公开（公告）日：2005-06-02

  The invention relates to a imidazo[1,2- a ]pyrimidone derivative represented by formula (I) or a salt thereof: R 1 wherein X represents a bond, an ethenylene group, an ethenylene group, a methylene group optionally substituted; a carbonyl group, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group or a nitrogen atom being optionally substituted; R 1 represents a 2, 4 or 5-pyrimidinyl optionally substituted; R 2 represents a C 1-6 alkyl group, a C 1-2 perhalogenated alkyl group,a C 1-3 halogenated alkyl group, a benzyl group, a benzene ring, a naphthalene ring, 5,6,7,8-tetrahydronaphthalene ring, a pyridine ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring, the benzyl group and the rings being optionally substituted; and n represents 0 to 3. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明涉及一种咪唑并[1,2-a]嘧啶酮衍生物，其由式(I)或其盐表示：R1其中，X表示键，乙烯基，乙烯基，亚甲基（可选取代），羰基，氧原子，硫原子，磺酰基，亚磺酰基，或氮原子（可选取代）；R1表示2，4或5-嘧啶基（可选取代）；R2表示C1-6烷基，C1-2全氟烷基，C1-3卤代烷基，苄基，苯环，萘环，5,6,7,8-四氢萘环，吡啶环，吲哚环，吡咯环，噻吩环，呋喃环或咪唑环，苄基和环可选取代；n表示0至3。本发明还涉及一种药物，其包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。
• USE OF 7-(PYRIMIDIN-4 YL)-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONES AS GSK-3BETA INHIBITORS
  申请人：LOCHEAD Alistair

  公开号：US20080318980A1

  公开（公告）日：2008-12-25

  The invention relates to a imidazo[1,2-a]pyrimidone derivative represented by formula (I) or a salt thereof: Wherein: X represents a bond, an ethenylene group, an ethynylene group, a methylene group optionally substituted; a carbonyl group, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group or a nitrogen atom being optionally substituted; R1 represents a 2, 4 or 5-pyrimidinyl optionally substituted; R2 represents a C 1-6 alkyl group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a benzyl group, a benzene ring, a naphthalene ring, 5,6,7,8-tetrahydronaphthalene ring, a pyridine ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring, the benzyl group and the rings being optionally substituted; and n represents 0 to 3. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明涉及一种以公式（I）表示的咪唑并[1,2-a]嘧啶酮衍生物或其盐：其中：X代表键，乙烯基，乙炔基，甲基基团（可选地取代），羰基基团，氧原子，硫原子，磺酰基团，亚磺酰基团或氮原子（可选地取代）；R1代表2,4或5-嘧啶基（可选地取代）；R2代表C1-6烷基，C1-2全氟烷基，C1-3卤代烷基，苄基，苯环，萘环，5,6,7,8-四氢萘环，吡啶环，吲哚环，吡咯环，噻吩环，呋喃环或咪唑环，其中苄基和环可选地取代；n代表0到3。本发明还涉及一种药物，其包含上述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。
• 1-(ALKYL), 1-(HETEROARYL)ALKYL AND 1-[(ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMIDAZO[1,2-A]PYRIMIDIN-5(1H)-ONE DERIVATIVES
  申请人：Sanofi-Aventis

  公开号：EP1480981A1

  公开（公告）日：2004-12-01
• US7429663B2
  申请人：——

  公开号：US7429663B2

  公开（公告）日：2008-09-30